Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05130450 · ClinicalTrials.gov registry record · Phase 3
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)
A Phase 3 study of Familial Chylomicronemia Syndrome, sponsored by Ionis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT05130450: Active Phase 3 study of Familial Chylomicronemia Syndrome, sponsored by Ionis Pharmaceuticals.
NCT05130450 is a Phase 3 study of Familial Chylomicronemia Syndrome that is active but no longer recruiting, run by Ionis Pharmaceuticals. The registered enrollment target is 60 participants, below the 67-participant average among 4 other Familial Chylomicronemia Syndrome trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05130450, a Phase 3 study of Familial Chylomicronemia Syndrome, is active but no longer recruiting, sponsored by Ionis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of olezarsen (formerly known as AKCEA-APOCIII-LRx) on the percent change in fasting triglycerides (TG) from baseline.
Conditions Studied
Interventions
- DRUG Olezarsen
Study Locations (20)
Other
- Groupement Hospitalier Est- Pharmacie Secteur Essais Clinique - Bron
- Hôpital Bicêtre - Le Kremlin-Bicêtre
- Pharmacie Hopital de la Conception - Marseille
- Via Sergio Pansini 5 - Naples
- UOC di Farmacia AOUP PAOLO GIACCONE - Palermo
- Azienda Ospedaliero Universitaria Policlinico Umberto I - Rome
- Oslo Hospital Pharmacy Rikshospitalet - Oslo
- Hospital da Senhora da Oliveira Guimaraes - Creixomil
Quebec
- Ecogene-21 - Chicoutimi
- Institute de Recherches Cliniques de Montreal - Montreal
- Nathalie Saint-Pierre - Montreal
- Clinique des Maladies Lipidiques de Quebec Inc. - Québec
New York
- CTSI Investigational Pharmacy - New York
- Milstein Hospital - New York
California
- Diabetes/Lipid Management & Research Center - Huntington Beach
Florida
- Excel Medical Clinical Trials, LLC - Boca Raton
Illinois
- Department of Pharmacy - Park Ridge
Kansas
- University of Kansas Medical Center (KUMC) - Kansas City
Pennsylvania
- IDS Central - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2028-02 |
| Phase | Phase 3 |
What the registry record for NCT05130450 still lists
NCT05130450 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 67-participant average among 4 other Familial Chylomicronemia Syndrome trials with a reported enrollment target (10% lower).
The record links to 1 condition, with Familial Chylomicronemia Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Olezarsen is the first listed.
NCT05130450 names 20 study sites across 9 states, led by Other, Quebec, New York.
Frequently Asked Questions
What is clinical trial NCT05130450 about?
NCT05130450 is a clinical study titled "A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)". The purpose of this study is to evaluate the effect of olezarsen (formerly known as AKCEA-APOCIII-LRx) on the percent change in fasting triglycerides (TG) from baseline.
What is the current status of trial NCT05130450?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2021-11-18. Estimated completion is 2028-02.
What conditions does trial NCT05130450 study?
This clinical trial studies the following conditions: Familial Chylomicronemia Syndrome.
What interventions are being tested in trial NCT05130450?
The interventions under investigation include: Olezarsen (DRUG).
Who is sponsoring clinical trial NCT05130450?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05130450 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Kansas, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Familial Chylomicronemia Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen
ACTIVE NOT RECRUITING · Phase 3
-
The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome
COMPLETED · Phase 3
-
The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome
COMPLETED · Phase 3
-
Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI